We employ a unique, science-driven approach to engineer the endolysin to be effective against a specific target (with no off-target effects) and to be effective in the specific therapeutic environment within which it needs to be effective. This innovative approach holds immense promise in bringing forward new therapeutics in areas of great unmet medical needs like in Atopic Dermatitis.
We create endolysins optimized for specific drug targets and engineered to be effective in the environment within which they operate using advanced molecular engineering techniques. Our molecule selectively targets the harmful, triggering pathogen (such as S. aureus in the case of Atopic Dermatitis) which exacerbate acute and chronic disease aggravation & progression. Due to the unique mode of action of our Engineered Endolysins, there is a very low propensity for drug resistance development which is critical in chronic therapies such as Atopic Dermatitis. Additionally, our lead molecules MEndoB is specifically engineered to be highly effective in the acidic environment of diseased skin in Dermatology.
Micreos is developing engineered endolysin-based treatments for patients suffering from diseases that are caused or aggravated by pathogenic triggers. Our lead indication is Atopic Dermatitis (AD).
Patients with Atopic Dermatitis have a disturbed skin barrier function as a genetic predisposition. The pathogen S. aureus then actively colonises the skin of patients with Atopic Dermatitis thereby attacking the weakened skin, worsening the barrier dysfunction and increasing vulnerability and permeability. It is well established in science and in medicine that S. aureus plays a significant role in the pathophysiology and severity of the Atopic Dermatitis condition. S. aureus produces toxins, proteases, superantigens and virulence factors which contribute towards inflammation, skin barrier dysfunction and pruritus / itch.
Due to the chronic nature of the disease AD has a significant long-term impact on the quality of life of patients in health-related aspects such as physical, psychosocial, and mental functioning. This means it is imperative to have treatments that are well tolerated, are safe and effective and that can be used in the long-term with no drug resistance issues.
Micreos’ MEndoB is a first-in-class and potentially best-in-class molecule with a completely new mode of action to existing therapies. Through our clinical development we want to give all AD patients a treatment option that:
With these benefits, our MEndoB has the potential to be used across the treatment paradigm for children and for adults with mild, moderate or severe AD.
We welcome collaboration with partners who share our ambition, please contact CEO Matt Regan:
m.regan@micreos.com